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A B S T R A C T
The ketogenic diet (KD) and the modiﬁed Atkins diet are effective therapies for intractable epilepsy. We
compared retrospectively the KD and modiﬁed Atkins diet in 27 children and also assessed serum long
chain fatty acid proﬁles. After 3 months, using an intent-to-treat analysis, the KD was more successful,
with>50% seizure reduction in 11/17 (65%) vs. 2/10 (20%) with themodiﬁed Atkins diet, p = 0.03. After 6
months, however, the difference was no longer signiﬁcant: 7/17 (41%) vs. 2/10 (20%) (p = 0.24). We
observed a preventive effect of both diets on the occurrence of status epilepticus. After 1 and 3months of
either diet, responders experienced a signiﬁcant decrease in serum arachidonic acid concentration
compared to non-responders. The KD andmodiﬁed Atkins diet led to seizure reduction in this small pilot
series, with slightly better results after 3 months with the KD, but not after 6 months. The decrease of
serum arachidonic acid levels might be involved in the anticonvulsive effects of KD or modiﬁed Atkins
diet.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journa l homepage: www.e lsev ier .com/ locate /yse iz1. Introduction
Approximately 30% of patients with epilepsy have refractory
epilepsy, i.e. seizures persist despite accurate diagnosis and
carefully monitored treatment with antiepileptic (AEDs) drugs.1,2
The ketogenic diet (KD) is a high-fat, adequate-protein and very
low-carbohydrate diet that has been used for many years to treat
intractable epilepsy in children. The KD has been shown to be
effective in retrospective, prospective and randomized controlled
studies.3–6 In a randomized controlled trial, after 3 months of the
KD, 38% of patients had >50% seizure reduction compared with 6%
of the controls, while 7% of patients had >90% seizure reduction
compared with none of the controls.5 In Korean and American
multicentric studies, more than 40–50% of patients had a >50%
reduction in seizure frequency after 6 and 12 months.6,7
More recently, the modiﬁed Atkins diet has been used to treat
intractable epilepsy.8–13 The modiﬁed Atkins diet induces ketosis
without ﬂuid, calorie or protein restriction, nor the requirement for
fasting or food weighting. Daily carbohydrates are limited and* Corresponding author at: Service de Neurologie Pe´diatrique et des Maladies
Me´taboliques, CHU Hoˆpital Robert Debre´, 48 boulevard Se´rurier, 75935 Paris Cedex
19, France. Tel.: +33 1 40 03 57 07; fax: +33 1 40 03 47 74.
E-mail address: auvin@invivo.edu (S. Auvin).
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doi:10.1016/j.seizure.2009.01.004high-fat intake encouraged. Themodiﬁed Atkins diet was designed
to be a less restrictive alternative than the KD. Early studies have
suggested efﬁcacy and safety in both children and adults.8–13
The mechanisms by which the KD and modiﬁed Atkins diet
exert their anti-seizure effects are not clear. Among the possible
mechanisms of action, it has been hypothesized that various fatty
acids, by inﬂuencing neuronal excitability, may constitute part of
beneﬁcial effects of KD on seizure control.14–21 In a study of 9
children on KD, elevated blood polyunsaturated fatty acid (PUFA)
was found. The rise in arachidonic acid (AA) was correlated with
seizure control.22 However, a decrease in serumAA and an increase
of linoleic (LA) and eicosapentaenoic (EPA) acids were found in
another study including 25 patients.23 In the latter, no correlation
between serum fatty acids levels and seizure control was found.
We report our experience using both classic KD and modiﬁed
Atkins diet in children with refractory epilepsy. Our aim was to
compare the relative efﬁcacy of the diets and to evaluate serum
long chain fatty acids proﬁles.
2. Methods
2.1. Patients
This retrospective study took place at the Pediatric Neurology
Department in Lille University Hospital, France. The subject cohortvier Ltd. All rights reserved.
Fig. 1. Seizure reduction in patients remaining on KD and onmodiﬁed Atkins diet at
1, 3, 6 and 12 months.
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had been experiencing more than 2 seizures per week which could
not be controlled by at least three anticonvulsant drugs. All seizure
types were permitted. No child with prior exposure to either the
KD or the modiﬁed Atkins diet was included.
2.2. Study design
The seizure frequency was determined from parental and
medical notes (seizure calendar) at baseline (1 month) and during
the follow-up (1, 3, 6 and 12 months on the diet). Children with a
50% seizure reduction were classiﬁed as non-responders and
those with a >50% seizure reduction as responders.
The occurrence of convulsive status epilepticus was compared
before and after the start of the diets. We included in this analysis
the patients that remain at least 3 months on diet.
At our institution, a non-fasting KD protocol was used from
September 2002 to January 2007 but was later replaced by the
modiﬁed Atkins diet. The classic KD was introduced without
initial fasting and ﬂuid restriction. The total caloric amount was
given in three days (day 1: 1/3; day 2: 2/3; day 3: 3/3). All
patients received the KD with a lipid-to-nonlipid ratio of either
4:1 or 3:1.
The modiﬁed Atkins diet consisted of 60% fat, 30% protein, and
10% carbohydrates by weight, without the restriction of recom-
mended daily calories according to patient age. The modiﬁed
Atkins diet was also introduced without initial fasting. As
suggested by Kossoff et al.,12 for the ﬁrst month carbohydrates
were restricted to 10 g/day, but were permitted to increase by 5 g/
day at intervals of at least 1 month when the child was having
difﬁculty with the restriction of carbohydrates, to a maximum of
10% carbohydrates per day by weight.
Following the start of either diet, all patients were advised to
remain in the hospital for 3–4 days to ensure adequate diet
adaptation. A qualiﬁed dietician (EB) also educated the caregivers/
parents about preparation of the diet at home. Follow-up clinic
visits at 1, 3, 6 and 12 months after initiating either diet were
obtained to assess efﬁcacy, tolerability, and associated serum long
chain fatty acid proﬁle.
2.3. Fatty acids proﬁling
Earlymorning blood sampleswere obtained from children prior
to the initiation of the diet and were planned after 1, 3, 6 and 12
months on either diet. After addition of internal standard (C19:0;
20.2 mg/ml), serum lipids were extracted with chloroform/
methanol (2/1, v/v) using a method adapted from this described
by Folch et al.24 Lipids were hydrolyzed and methylated with
sulphuric acid and methanol. Fatty acid methyl esters obtained
were separated by gas–liquid chromatography using a 30-m
Supelco Ome´gawax TM 320 fused-silica capillary column. Analysis
was performed on a Varian 3400 gas chromatograph (Varian, Palo
Alto, CA) equipped with ﬂame ionization detector. Helium was
used as carrier gas and column conditions were optimized to
separate all the peaks of interest: C14:0, C16:0, C16:1, C18:0,
C18:1, C18:2 n-6, C18:3: n-3, C20:3 n-6, C20:5 n-3, C20:3 n-9,
C20:4 n-6, C22:6 n-3. Results are expressed as percentage of total
fatty acids (mean  S.E.M.).
2.4. Statistical analyses
Statistical Package for the Social Science (version 15.0) (SPSS
Chicago, IL)was used for all statistical analyses and a p-value<0.05
was regarded as statistically signiﬁcant. Categorical data were
analyzed using Fisher exact test. Means (S.E.M.) were analyzed
using Mann–Whitney test.3. Results
3.1. Patient demographics
Twenty-seven patients (15 females) were treated: 17 with the
KD fromSeptember 2002 to January 2007 and 10with themodiﬁed
Atkins diet from January 2007 to June 2008 (Table 1). For 2 patients
(patients 7 and 8), KD was replaced by the modiﬁed Atkins diet
after 5 and 11 months, respectively. The median age at seizure
onset was 6 months (range: birth-66 months). The epilepsy
syndromes of the included patients were: 30% infantile spasms (8/
27), 56% partial epilepsy (15/27), 11% generalized epilepsy (3/27)
and 3% Lennox–Gastaut syndrome (1/27). A median of 7 AEDs
(range: 3–14) had been attempted before diet initiation. The
median age at KD onset was 32 months (range: 11–153 months)
and at modiﬁed Atkins diet onset was 77 months (range: 4–182
months). Children were receiving a median of 3 AEDs at diet
initiation (range: 2–4) (Table 2).
3.2. Treatment efﬁcacy and duration
All children completed at least 1 month on diet. To date, 1
patient remains on the KD and 5 patients are still on the modiﬁed
Atkins diet. The median diet duration was 5 months (range: 1–24)
for the KD and 3 months (range: 1–6) for the modiﬁed Atkins diet.
Twenty-nine percent remained on the KD after 12 months
compared to 20% on the modiﬁed Atkins diet.
After 1 month, 10 of 17 (59%) children receiving the KD were
>50% improved, compared to 5/10 (50%) of those receiving the
modiﬁed Atkins diet (p = 0.28). Using an intent-to-treat analysis,
after 3months, 11 of 17 (64%) on the KDwere improved, compared
to 2 of 10 (20%)withmodiﬁed Atkins (p = 0.03). After 6months, the
difference was no longer signiﬁcant: 7/17 (41%) vs. 2/10 (20%)
(p = 0.24). Ten of 17 children have stopped the KD (seizure free
(n = 3), ineffective (n = 7), intolerance (n = 1)) whereas 5/10
stopped modiﬁed Atkins diet (ineffective (n = 4), intolerance
(n = 2)). After 12 months, 8 patients were still on diet (6 KD; 2
modiﬁed Atkins diet). The comparison was not possible due to the
small number of patients. None of our patient has had major side
effects. We observed mild digestive disorders in 2 patients on KD
and in 1 patient on the modiﬁed Atkins diet (Fig. 1).
There was no difference in the number of anticonvulsants
before and after diet treatment. The occurrence of convulsive
status epilepticus signiﬁcantly decreased after the diet initiation
(analysis done for 24 patients that remain at least 3 months on
diet). Before either diet, the median occurrences of status
epilepticus was 1 (range: 0–12) while the median was 0 (range:
0–2) while receiving dietary therapy (p = 0.005).
Table 1
Demographic data of the 27 included children.
Patient
no.
Sex Epilepsy
onset (year)
Epilepsy
typea
Etiology or epileptic syndrome Diet type Age onset
KD (year)
Previous
AEDs
Diet time
(months)b
Concomitant
AED at startc
1 F 0.1 IS 1p36 deletion KD 0.11 5 9 VGB, TPM
2 M 0.4 P Hypoxic-ischemic encephalopathy KD 1.8 5 1 VGB, TPM
3 F 1.4 P Cryptogenic Atkins 15.2 14 1 OXC, BZD
4 F 4 P Sturge Weber syndrome Atkins 5.10 8 ! LEV, VGB, STP
5 M 3 IS Unknown Atkins 6.1 8 1 VPA, GBP
6 F 2 days P Right hemimegalencephaly KD 1.5 4 3 VGB, PHB, BZ
7 M 15 days P Cryptogenic KD! A 0.3 6 ! VGB, BZD, STP
8 M 0.5 IS Mitochondrial respiratory chain defect KD! A 2.1 5 ! BZD, VGB, LTG
9 F 3 G Cryptogenic Atkins 9.8 5 3 VPA, LEV, LTG
10 M 0.6 IS! LG Tuberous sclerosis KD 3.3 6 12 VGB, PHT, BZD
11 M 0.5 P Hypoxic-ischemic encephalopathy KD 2.5 7 12 PHT, LTG
12 M 1.8 G Unknown KD 8.10 7 6 LTG, VPA
13 F Birth P Complex malformation Atkins 0.4 3 4 VGB, TPM
14 F 2.7 G Unknown Atkins 10.3 7 3 ETM, LTG, BZD, VPA
15 F 0.5 IS! LG HSV encephalitis Atkins 9.2 12 3 ETM, TPM, BZ, FLB
16 F 1.4 P Frontal cortical dysplasia KD 2.7 10 4 STP, BZD, ETM
17 F 0.11 P Hypoxic-ischemic encephalopathy Atkins 6.9 7 ! LEV, BZ, LTG, TPM
18 M 0.2 P Cryptogenic Atkins 1.3 4 ! TPM, STP, BZD
19 M 0.5 IS Cryptogenic KD 2 9 12 VPA, LTG, GBP
20 F 0.8 P Cryptogenic KD 3.1 6 2 LTG, TPM
21 F 0.1 P Cryptogenic KD 5.4 11 12 FLB, LTG, BZD
22 M 5.6 EPC Mitochondrial respiratory chain defect KD 12.4 7 ! ETM, TPM, BZD, STP
23 M 0.6 IS Tuberous sclerosis Atkins 0.9 5 2 LTG, HC, VGB
24 F 0.8 LG HSV encephalitis KD 12.9 14 4 TPM, FLB, ETM
25 F 1.1 P Unknown KD 2.8 6 3 TPM, STP
26 M 0.2 IS Lissencephaly KD 2.8 7 3 VGB, TPM, LTG
27 F 3 P Sturge Weber syndrome KD 3.1 6 24 TPM, LTG, BZD
a P: partial epilepsy; G: generalized epilepsy; LG: Lennox–Gastaut syndrome; EPC: epilepsy partialis continua, IS: infantile spasms.
b !: in process; KD! A: KD follow by modiﬁed Atkins diet.
c AEDs: VGB: vigabatrin; TPM: topiramate; PHB: phenobarbital; BZD: benzodiazepine; PHT: phenytoin; LTG: lamotrigine; VPA: valproic acid; STP: stiripentol; CBZ:
carbamazepine; ETM: ethosuximide; FLB: felbamate; LEV: levetiracetam; OXC: oxcarbazepine; GBP: gabapentine; HC: hydrocortisone.
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Patients 4, 7, 12, 15, and 17 had serum total lipid long chain
fatty acids proﬁle before and 1, 3, 6 and 12 months after treatment
initiation, respectively. Signiﬁcant changes in several fatty acids
were found (Fig. 2). As for the omega-6 (n-6) and omega-3 (n-3)
fatty acids: linoleic (LA; C18:2 n-6) and alpha-linolenic (ALA; C18:3
n-3) acids were increased at 1, 3, 6 and 12months, whereas homo-
linoleic acid (C20:3 n-6), arachidonic acid (AA; C20:4 n-6),
eicosapentaenoic acid (EPA; C20:5 n-3), docosahexaenoic acid
(DHA, C22:6 n-3) and eicosatrienoic acid (mead; C20:3 n-9) were
unchanged after 1, 3, 6 or 12 months on either diet. For the
monounsaturated fatty acids, consistent changes were seen in
palmitoleic acid (C16:1), which was signiﬁcantly reduced after 1, 6
and 12 months under treatment. Saturated fatty acids levels were
unchanged after 1, 3, 6 or 12 months under treatment.
3.4. Levels of serum fatty acid and efﬁcacy at 1 and 3 months
The levels of each fatty acid at 1 and 3 months of diet were
statistically compared according to responder (>50% seizure
reduction) and non-responder (50% seizure reduction) status
(Fig. 3). After 1 month, children who were responders (n = 7) had aTable 2
Demographic data comparison between KD and modiﬁed Atkins diet. Results are
expressed as a median.
Modiﬁed Atkins diet KD
Patients n = 10 n = 17
Previous AEDs 7 6
Age onset diets (months) 77 32
Treatment duration (months) 3 5
Still under treatment 5 1
Concomitant AEDs at start 3 3signiﬁcant increase of serum palmitoleic acid and a signiﬁcant
decrease of AA compared to non-responder (n = 8). AA values were
5.57  0.73% and 9.06  0.81% in responder and non-responder
patients, respectively. There was a slight decrease in serum EPA in
responders (p = 0.06). After 3 months, responders (n = 6) had lower
serum AA and DHA compared to non-responders (n = 6). AA values
were 6.17  0.63% and 8.99  1.10% and DHA values were
1.77  0.22% and 2.46  0.15% in responder and non-responders,
respectively. LA and ALA serum levels were not different between
groups after 1 and 3 months.
4. Discussion
The KD and the modiﬁed Atkins diet seem to exert overall
comparable efﬁcacy for childrenwith intractable epilepsy over a 6-
month period. Our overall results are similar to what has been
published in the United States and Asia for themodiﬁed Atkins diet
in children, although slightly fewer efﬁcacieswas seen in our series
beyond the 1-month point than elsewhere.8–13 This is the ﬁrst
report of the use of modiﬁed Atkins diet in children in Europe to
our knowledge.
Regarding the serum total lipid long chain fatty acid measure-
ments, an increase of serum LA, ALA, and palmitoleic acid was
observed for the patients on these diets. Children who responded
to these diets experienced a signiﬁcant decrease of AA concentra-
tion after 1 and 3 months while a signiﬁcant decrease of DHA
concentration was observed in responders after 3 months. It is
highly unlikely that AED are involved in PUFAmodiﬁcation as only
one patient received oxcarbazepine at that time (Table 1).
We agree with reports at other institutions by parents or
caregivers that the modiﬁed Atkins diet is well-tolerated by
children.9,12 In this study, diet duration was generally equal
between these groups, with 20–29% of children remaining on
either diet after 12 months. Two children were able to transition
Fig. 2. Level of fatty acids in patient serum before and at 1, 3, 6 and 12 months after the initiation of the KD or the modiﬁed Atkins diet. (A) Saturated and monounsaturated
fatty acids; (B) Polyunsaturated fatty acids. Start n = 17, 1 month n = 15; 3 months n = 12; 6 months n = 7; 12 months n = 4. *p  0.05 in comparison with start;&, p = 0.02 in
comparison with 1month. Myristic: myristic acid (C14:0); palmitic: palmitic acid (C16:0); palmitoleic: palmitoleic acid (C16:1); stearic: stearic acid (C18:0); oleic: oleic acid
(C18:1); LA + ALA: linoleic acid (C18:2 n-6) + alpha-linolenic acid (C18:3 n-3); homo lino: homo linoleic acid (C20:3 n-6); EPA: eicosapentaenoic acid (C20:5 n-3); mead:
eicosatrienoic (C20:3 n-9); AA: arachidonic acid (C20:4 n-6); DHA: docosahexaenoic acid (C22:6 n-3).
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efﬁcacy.
Our results also demonstrated that KD and the modiﬁed Atkins
diet may have a preventative effect on the occurrence of status
epilepticus (SE). In addition to the anticonvulsant effect of the diets,
the possible prevention of morbidity and mortality from SE may be
an important additional beneﬁt. Few clinical data are available on
the use of KD or the modiﬁed Atkins diet in children with SE, with
only our single case report of the use of KD in an adult.25
Both in vivo14–17,20,26 and in vitro18,19,21 experimental studies
have demonstrated anticonvulsant effects of PUFA. However, the
anticonvulsant properties of PUFA in clinical trials are conﬂict-
ing.27–29 A previous study including 9 patients receiving the KD
reported a signiﬁcant increase of AA and DHA after 1 month. The
increase in total serum AA was correlated with improvement
seizure control.22 Another study of 25 children receiving the KD
reported a decrease of AA.23 No correlation between serum fatty
acids and seizure frequency was found.23 In our study, responder
patients showed a signiﬁcant decrease of serum AA after 1 and 3
months. We also found a signiﬁcant decrease of DHA concentra-
tions in responder patients after 3 months.
Among the experimental studies showing anticonvulsant
effects of PUFA, we recently showed the absence of links with
the brain phospholipids modiﬁcation. However, the rats treated by
KD or by an ALA/LA mixture experienced a decrease of serum AA
concentrations.14 Another recent study showed a dose dependant
anticonvulsant effect of LA and ALA (SR-3 mixture) associated to a
raise in n-3 PUFA unesteriﬁed fatty acids in the brain inpentylenetetrazole (PTZ) induced seizure in rats.17 While a study
usingmice showed a decrease of serumAA concentration after EPA
or DHA (n-3 PUFA) treatment, there was no change in PTZ,
ﬂuorothyl or 6 Hz seizure thresholds.30 In vitro studies have shown
that extracellular application of PUFA produces a concentration-
dependent shift of the voltage dependence of inactivation of both
Na+ and Ca2+ currents to more hyperpolarized potentials. The use
of n-6 PUFA (LA) were less effective on both Na+ and Ca2+ currents
inhibition than n-3 PUFA.18 Others studies reported that AA (n-6)
increased cellular excitability by inhibiting depolarization-acti-
vated K+ currents and transient K+ currents in both CA1 pyramidal
neurons and inhibitory interneurons.31,32 Further study is needed
to evaluate if KD and/or modiﬁed Atkins diet efﬁcacy may be
related to a serum AA decrease that could lead to decrease
neuronal excitability.
In conclusion, both the KD and modiﬁed Atkins diet appear to
demonstrate similar efﬁcacy in children with intractable epilepsy
over a 6-month period. The modiﬁed Atkins diet was well-
tolerated as well. As a result of our ﬁndings, it is now our primary
dietary therapy for children. Furthermore, it seems that seizures do
not appear to increasewhen themodiﬁed Atkins diet is substituted
for the KD, as has been noted previously in one child.10 Further
study is needed to assess this issue, including switching patients
who do not respond to the modiﬁed Atkins diet to the classical KD.
Finally, we observed that responder patients treated by KD or
modiﬁed Atkins diet had decreased serum AA levels. The decrease
of AA should be further explored in order to understand its role in
the anticonvulsant effect of dietary therapies.
Fig. 3. Levels of fatty acids in responders and in non-responders 1 and 3 months after initiation of the KD and the modiﬁed Atkins diet. (A) Data after 1 month of treatment,
non-responders (50%) n = 7; responders (>50%) n = 7. (B) Data after 3 months of treatment, non-responders (50%) n = 6; responders (>50%) n = 6. *p  0.05 in comparison
with non-responder group (50). Myristic: myristic acid (C14:0); palmitic: palmitic acid (C16:0); palmitoleic: palmitoleic acid (C16:1); stearic: stearic acid (C18:0); oleic:
oleic acid (C18:1); LA + ALA: linoleic acid (C18:2 n-6) + alpha-linolenic acid (C18:3 n-3); homo lino: homo linoleic acid (C20:3 n-6); EPA: eicosapentaenoic acid (C20:5 n-3);
mead: eicosatrienoic (C20:3 n-9); AA: arachidonic acid (C20:4 n-6); DHA: docosahexaenoic acid (C22:6 n-3).
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